LifeSpan BioSciences, Inc. And MBL International Corporation Announce Multi-Year Licensing And Asset Agreement
Published: Feb 06, 2006
SEATTLE & WOBURN, Mass.--(BUSINESS WIRE)--Feb. 6, 2006--LifeSpan BioSciences, Inc. ("LifeSpan") and MBL International Corporation ("MBLI"), a wholly owned subsidiary of Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan), announced today a multi-year relationship in which MBLI will distribute antibodies to druggable gene targets that LifeSpan has developed and commercialized. As part of the new relationship, MBLI has purchased LifeSpan's existing inventory of more than 900 antibodies including the exclusive research reagent sales rights. Financial terms of the transaction were not disclosed.